279 related articles for article (PubMed ID: 17618043)
1. Inflammation and chronic prostatic diseases: evidence for a link?
Sciarra A; Di Silverio F; Salciccia S; Autran Gomez AM; Gentilucci A; Gentile V
Eur Urol; 2007 Oct; 52(4):964-72. PubMed ID: 17618043
[TBL] [Abstract][Full Text] [Related]
2. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
3. Prostate growth and inflammation.
Sciarra A; Mariotti G; Salciccia S; Autran Gomez A; Monti S; Toscano V; Di Silverio F
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):254-60. PubMed ID: 17935971
[TBL] [Abstract][Full Text] [Related]
4. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
6. The correlation between metabolic syndrome and prostatic diseases.
De Nunzio C; Aronson W; Freedland SJ; Giovannucci E; Parsons JK
Eur Urol; 2012 Mar; 61(3):560-70. PubMed ID: 22119157
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
8. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
9. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
10. Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
Hamid AR; Umbas R; Mochtar CA
Acta Med Indones; 2011 Jan; 43(1):59-65. PubMed ID: 21339547
[TBL] [Abstract][Full Text] [Related]
11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
12. [Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].
Yang L; Zhao K; Zhang A; Liu LR; Liu ZH; Han P; Wei Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):760-3, 768. PubMed ID: 24325107
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
15. Prostate carcinogenesis and inflammation: emerging insights.
Palapattu GS; Sutcliffe S; Bastian PJ; Platz EA; De Marzo AM; Isaacs WB; Nelson WG
Carcinogenesis; 2005 Jul; 26(7):1170-81. PubMed ID: 15498784
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
17. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
18. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
Kramer G; Mitteregger D; Marberger M
Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170
[TBL] [Abstract][Full Text] [Related]
19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
20. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Kramer G; Marberger M
Curr Opin Urol; 2006 Jan; 16(1):25-9. PubMed ID: 16385197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
